RNASET2 and nonpapillary renal cell carcinoma: These results suggest that RNASET2 upregulation not only predicts a poor prognosis for ccRCC, but its expression level might also serve as a potent biomarker to guide the clinical treatment of patients with metastatic ccRCC.